Immune System Disorder and Cancer-Associated Cachexia

• Published in: Cancers Vol. 16; no. 9; p. 1709
• Main Authors: Zhang, Lingbing, Bonomi, Philip D.
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.05.2024
• Subjects: Adipocytes; Adipose tissue; Anorexia; Body fat; Cachexia; Cancer; Cancer therapies; Cytokines; Development and progression; Drug therapy, Combination; Health aspects; Immune response; Immune system; Immunomodulation; Immunosuppressive agents; Immunotherapy; Inflammation; Interleukin 6; Interleukin 8; Ketorolac; Leukocytes (neutrophilic); Lymphocytes; Metabolism; Morbidity; Neutrophils; NF-κB protein; Oncology, Experimental; Pancreatic cancer; Patients; Suppressor cells; Tofacitinib; Transforming growth factor-b; Transforming growth factors; Tumor necrosis factor; Tumor necrosis factor-α; Tumors; γ-Interferon; CAC; TNF-α; inflammation; cytokines; immune disorder; IL-6; muscle wasting
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers16091709

Cancer-associated cachexia (CAC) is a debilitating condition marked by muscle and fat loss, that is unresponsive to nutritional support and contributes significantly to morbidity and mortality in patients with cancer. Immune dysfunction, driven by cytokine imbalance, contributes to CAC progression. This review explores the potential relationship between CAC and anti-cancer immune response in pre-clinical and clinical studies. Pre-clinical studies showcase the involvement of cytokines like IL-1β, IL-6, IL-8, IFN-γ, TNF-α, and TGF-β, in CAC. IL-6 and TNF-α, interacting with muscle and adipose tissues, induce wasting through JAK/STAT and NF-κB pathways. Myeloid-derived suppressor cells (MDSCs) exacerbate CAC by promoting inflammation. Clinical studies confirm elevated pro-inflammatory cytokines (IL-6, IL-8, TNFα) and immune markers like the neutrophil-to-lymphocyte ratio (NLR) in patients with CAC. Thus, immunomodulatory mechanisms involved in CAC may impact the anti-neoplastic immune response. Inhibiting CAC mechanisms could enhance anti-cancer therapies, notably immunotherapy. R-ketorolac, a new immunomodulator, reversed the weight loss and increased survival in mice. Combining these agents with immunotherapy may benefit patients with cancer experiencing CAC. Further research is vital to understand the complex interplay between tumor-induced immune dysregulation and CAC during immunotherapy.